[1]张敏佳,龚洁秋.葶黄清肺汤联合平喘咳外敷散治疗喘息性支气管炎疗效研究[J].陕西中医,2024,(7):922-925.[doi:DOI:10.3969/j.issn.1000-7369.2024.07.013]
　ZHANG Minjia,GONG Jieqiu.Curative effect study on Tinghuang Qingfei decoction combined with Pingchuanke external application powder in treatment of asthmatic bronchitis[J].,2024,(7):922-925.[doi:DOI:10.3969/j.issn.1000-7369.2024.07.013]
点击复制

葶黄清肺汤联合平喘咳外敷散治疗喘息性支气管炎疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年7期
页码:
922-925
栏目:
临床研究
出版日期:
2024-07-05

文章信息/Info

Title:
Curative effect study on Tinghuang Qingfei decoction combined with Pingchuanke external application powder in treatment of asthmatic bronchitis
作者:
张敏佳; 龚洁秋
(常熟市中医院儿内科,江苏 常熟 215500)
Author(s):
ZHANG Minjia; GONG Jieqiu
(Department of Pediatrics,Changshu Hospital of Traditional Chinese Medicine,Changshu 215500,China)
关键词:
喘息性支气管炎;  葶黄清肺汤;  平喘咳外敷散;  肺功能;  炎症因子;  不良反应
Keywords:
Asthmatic bronchitis;  Tinghuang Qingfei decoction;  Pingchuanke external application powder;  Lung function;  Inflammatory factors;  Adverse effect
分类号:
R 562.2
DOI:
DOI:10.3969/j.issn.1000-7369.2024.07.013
文献标志码:
A
摘要:
目的:探究葶黄清肺汤联合平喘咳外敷散在喘息性支气管炎患儿中的应用价值。方法:择取82例喘息性支气管炎患儿,按照随机数字表法分为联合组(n=41)、对照组(n=41),联合组采用葶黄清肺汤联合平喘咳外敷散治疗,对照组开展平喘咳外敷散治疗。观察两组喘息性支气管炎患儿临床治疗效果,症状消退时间,肺功能[潮气量(TV)、呼气峰流速(PEF)和第1秒用力呼气容积(FEV1)],促炎因子水平[白介素-6(IL-6)、降钙素原(PCT)、肿瘤坏死因子-α(TNF-α)]和不良反应发生情况。结果:用药后联合组临床疗效较对照组高,症状消退所耗时间较对照组短(P<0.05)。用药后,联合组患儿TV、PEF和FEV1分别为(7.69±1.17)ml/kg、(2.81±0.42)L/s和(1.95±0.42)L,较对照组的(6.64±1.92)ml/kg、(2.34±0.45)L/s和(1.67±0.45)L高,差异有统计学意义(均P<0.05)。联合组患儿用药后IL-6、PCT和TNF-α分别为(14.27±3.27)ng/L、(0.67±0.13)ng/ml和(11.81±2.97)ng/L,均低于对照组的(19.69±3.52)ng/L、(1.47±0.22)ng/ml和(15.06±4.29)ng/L,差异有统计学意义(均P<0.05)。两组喘息性支气管炎患儿不良反应发生率比较,差异无统计学意义(P>0.05)。结论:葶黄清肺汤联合平喘咳外敷散能有效缩短喘息性支气管炎患儿预后症状消失时间,改善肺功能和炎性症状。
Abstract:
Objective:To explore application value of Tinghuang Qingfei decoction combined with Pingchuanke external application powder in children with asthmatic bronchitis.Methods:82 children with asthmatic bronchitis were selected and classified into combined group(n=41)and control group(n=41)according to random number table method.The combined group were treated with Tinghuang Qingfei decoction combined with Pingchuanke external application powder therapy,while the control group carried out Pingchuanke external application powder therapy.The clinical treatment effect,symptom regression time,lung function [tidal volume(TV),peak expiratory flow(PEF)and forced expiratory volume in the first second(FEV1)],pro-inflammatory factors [interleukin-6(IL-6),procalcitonin(PCT),tumor necrosis factor-α(TNF-α)] and occurrence of adverse reactions were observed in the two groups.Results:After treatment,clinical efficacy in the combined group were higher,and the time of symptom regression shorter than that in the control group(P<0.05).After treatment,TV,PEF and FEV1 in the combined group with(7.69±1.17)ml/kg,(2.81±0.42)L/s and(1.95±0.42)L,which were higher than(6.64±1.92)ml/kg,(2.34±0.45)L/s and(1.67±0.45)L in the control group,difference statistically significant(all P<0.05).The levels of IL-6,PCT and TNF-α in the combined group after medication were(14.27±3.27)ng/L,(0.67±0.13)ng/ml and(11.81±2.97)ng/L,which were lower than(19.69±3.52)ng/L,(1.47±0.22)ng/ml and(15.06±4.29)ng/L in the control group,difference statistically significant(all P<0.05).There were no statistical differences in the incidence rates of adverse reactions between groups of children with asthmatic bronchitis,difference not statistically significant(P>0.05).Conclusion:Tinghuang Qingfei decoction combined with Pingchuanke external application powder can effectively shorten prognosis symptom disappearance time and improve lung function and inflammatory symptoms in children with asthmatic bronchitis.

参考文献/References:

[1] SAGLANI S,FLEMING L,SONNAPPA S,et al.Advances in the aetiology management and prevention of acute asthma attacks in children [J].Lancet Child Adolesc Health,2019,3(5):354-364.
[2] 霍姝琦,舒桂华,王艳,等.氨溴索联合布地奈德混悬液雾化吸入对重型新生儿肺炎患儿的影响[J].中国临床药理学杂志,2022,38(16):1847-1850.
[3] 方辉,刘梦莹,郑武田.人干扰素α2b联合特布他林治疗嗜酸粒细胞性支气管炎患儿的临床研究[J].中国临床药理学杂志,2023,39(23):3361-3364.
[4] 边红恩,陈团营,单海军.小青龙汤联合阿奇霉素治疗喘息性支气管炎疗效及对患者外周血辅助性T细胞表达和肺功能的影响[J].陕西中医,2019,40(5):607-609.
[5] 顾盼瑾,张立红,胡锡池,等.黄芪多糖联合替加环素对白细胞减少性鲍曼不动杆菌感染肺炎大鼠的疗效及机制研究[J].陕西医学杂志,2023,52(10):1319-1325.
[6] 翟婷,王盼,王源,等.基于“邪伏肺络”理论论治支气管扩张症[J].北京中医药大学学报,2023,46(6):853-858.
[7] 江载芳,申昆玲.诸福棠实用儿科学[M].北京:人民卫生出版社,2015:1172-1180.
[8] 汪受传,虞坚尔.中医儿科学[M].北京:中国中医药出版社,2012:91-93.
[9] 尤焱南,周涛,赵霞.《中医儿科病证诊断疗效标准?哮喘(修订)》框架意见专家调查问卷结果分析[J].浙江中医药大学学报,2019,43(4):331-335.
[10] BARCIK W,BOUTIN R C T,SOKOLOWSKA M,et al.The role of lung and gut microbiota in the pathology of asthma[J].Immunity,2020,52(2):241-255.
[11] 黄美芬,王力宁,邓玉芝,等.平喘咳外敷散内外合治小儿哮喘发作期咳喘证的疗效研究[J].中国中西医结合儿科学,2016,8(6):564-566.
[12] 徐进,何守再,郑晓鸿,等.加减葶苈清肺汤治疗肝火犯肺型特发性间质性肺炎的疗效及对肺功能、血清SAA、KL-6的影响[J].四川中医,2020,38(5):103-106.
[13] 王增玲,吴航,陶华景.麻杏甘石汤治疗小儿热哮型急性喘息性支气管炎疗效及对血清EOS、NO水平的影响[J].中国中医急症,2022,31(2):268-271.
[14] 刘志刚,柴程芝.基于药性结合药理的麻黄药证研究[J].中国中药杂志,2019,44(18):3883-3889.
[15] 林瑞婷,陈芝强,林丽珠.基于网络药理学探讨桔梗-苦杏仁与肺癌相关分子机制[J].中国实验方剂学杂志,2020,26(19):217-224.
[16] 刘施吟,成晓萌,陈宪海.基于网络药理学的前胡治疗支气管哮喘的分子机制研究[J].中国医院药学杂志,2020,40(14):1528-1533.
[17] 贠小荣.细辛脑注射液治疗小儿支气管肺炎60例[J].陕西医学杂志,2012,41(7):925.
[18] CHOY E H,BENEDETTI F,TAKEUCHI T,et al.Translating IL-6 biology into effective treatments[J].Nat Rev Rheumatol,2020,16(6):335-345.
[19] 林雪竹,李蔚群,关永霞,等.葶苈子化学成分及药理作用研究进展[J].中国现代中药,2022,24(3):550-558.
[20] 李淑娣,陈欣菊,刘江凯,等.虎杖活性成分治疗非酒精性脂肪性肝病的相关信号通路及相互作用[J].临床肝胆病杂志,2022,38(4):902-907.
[21] 伍磊.紫苏子汤对哮喘小鼠TNF-α、白细胞介素-8、白介素-1β表达的影响[J].陕西中医,2019,40(2):152-155.
[22] 陆晓珊,林也,唐琳,等.鱼腥草的化学成分与安全性研究进展[J].中华中医药学刊,2021,39(3):144-147.
[23] 朱亚南,杨七妹,张硕,等.黄芩苷与黄芩素药理作用及机制研究进展[J].时珍国医国药,2020,31(4):921-925.
[24] 吴娇,王聪,于海川.金银花中的化学成分及其药理作用研究进展[J].中国实验方剂学杂志,2019,25(4):225-234.
[25] 丁倩云,马双成,许风国,等.桑白皮的化学成分、药理及质量控制研究进展[J].药物分析杂志,2021,41(7):1114-1124.

备注/Memo

备注/Memo:
基金项目:江苏省卫生健康委员会科研课题(Z2022-04); 江苏省苏州市科技计划项目(SYSD2020225)
更新日期/Last Update: 2024-07-09